- Laser Eye Surgery news are updated once a hour
- We deliver news from more than 500 sources on laser eye surgery
NewsAdvertisers: |
Senator touts medical accounts...
REGISTER A GLOBAL USER ACCOUNT
... CCL extend endoscope lifespan for $9bn market...
CCL extend endoscope lifespan for $9bn market
22 February 2006
Latest News In High Tech
CCL extend endoscope lifespan for $9bn market
By Alice Walker, 22 February 2006, viewed 28 times, emailed 47 times
Cambridge Consultants is working with NDO Surgical to apply novel technologies to extend the time between service for its award-winning endoscopic device, which treats heartburn and other effects of gastroesophageal reflux disease (GERD). Redesign extends the life of NDO Surgical’s flagship laparoscopic surgery device for GERD as manufacturer pushes to expand the market Cambridge Consultants is working with NDO Surgical to apply novel technologies to extend the time between service for its award-winning endoscopic device, which treats heartburn and other effects of gastroesophageal reflux disease (GERD). With non-invasive procedures to treat GERD making significant gains in market acceptance, the enhancements to NDO Surgical's Full-Thickness Plicator system allow the company to better compete in the market - with a more rugged device that is capable of longer life in the field. The existing Plicator device, which was first approved by the FDA in 2003, has received enthusiastic adoption by surgeons as the endoluminal therapy of choice, and has begun displacing other GERD treatment options because of the device's ease of use and clinical performance. GERD is a catch-all condition referring to assorted symptoms including heartburn, regurgitation, chest pain, hoarseness, wheez... NovaMed Acquires Ambulatory Surgery Center in Texas; To Acquire ......
/* GENERAL FONT AND LINK SETTINGS */
BODY,
PRE,
TR,
TD,
TH,
P {font-family: Arial, Helvetica, sans-serif;
font-size: small;
color: #000000;
font-weight: normal;
font-style: normal}
P {margin-top: 0px; margin-bottom: 1em}
TH {font-weight: bold}
.epi-fontSm,
.wsui-font-small {font-size: x-small}
.epi-font,
.wsui-font {font-size: small}
.epi-fontLg,
.wsui-font-large {font-size: medium}
a:link {color: #000066;
text-decoration: underline}
a:visited {color: #000066;
text-decoration: underline}
a:active,
a:hover {color: #660000;
text-decoration: underline}
a.epi-headline {font-weight: normal;
text-decoration: underline ! important} /* FOR TRAIL, PAGE, AND SECTION TITLES */ /* NAVIGATION TRAILS */ .epi-trail, .wsui-trail {font-family: Arial, Helvetica, sans-serif; font-size: small; color: #666666; font-weight: normal; margin-bottom: 0px} .epi-trail a, .wsui-trail a {color: #666666 ! important; text-decoration: none ! important} .epi-trail a:hover, .wsui-trail a:hover {color: #666666; text-decoration: underline ! important} .epi-trailOn, .wsui-trail-current {font-family: Arial, Helvetica, sans-serif; font-size: small; color: #000000; font-weight: bold; margin-bottom: 0px} /* PAGE TITLES */ h1, .epi-pageTitle, .wsui-page-title {font-family: Arial, Helvetica, sans-serif; font-size: medium; color: #663300; font-weight: bold; margin-bottom: 0px} /* SECTION TITLES*/ h2, .epi-sectionTitle, .wsui-section-title {font-family: Arial, Helvetica, sans-serif; font... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news |
| Medicine |